Current Issues of Pharmacy and Medical Sciences

Pathophysiological aspects of the pancreas function in rats with monosodium glutamate-induced obesity

Curr Issues Pharm Med Sci Vol. 26, No. 4, Pages 365-368

Ivan Leschenko1, Victor Shevchuk1, Oleksandr Savcheniuk2, Tetyana Falalyeyeva2, Tetyana Beregova2

Bogomolets National Medical University, Ukraine

Taras Shevchenko National University of Kyiv, Ukraine

DOI: 10.12923/j.2084-980X/26.4/a.01


Our study demonstrates that neonatal treatment with monosodium glutamate (MSG) leads to the development of visceral obesity in adult rats. In rats’ pancreas of both sexes massive edema and inflammation were found, which are characteristic of acute pancreatitis. Marked intralobular and perivascular lipomatosis was also found. There was also marked leukocyte infiltration in rats with MSG-induced obesity. Morphometric analysis confirmed pathological changes in pancreatic tissue. The level of blood amylase, lipase and pancreatic amylase was increased by 92% (p<0.001), 312% (p<0.001) and 162% (p<0.001). So, neonatal treatment with MSG leads to the development of pancreatitis in adulthood of rats. We concluded that the development of pancreatitis in rats with MSG-induced obesity is the result of increase of synthetic and secretory processes in pancreatic cells.


monosodium glutamate, pancreas, pancreatitis.


  1. Araki H. et al.: Adiponectin plays a protective role in caerulein-induced acute pancreatitis in mice fed a high-fat diet. Gut, 57, 1431-1440, 2008.
  2. Brahm A., Hegele R.: Hypertriglyceridemia. Nutrients., 5, 981-1001, 2013.
  3. Ellis M.P., French J.J., Charnley R.M. Acute pancreatitis and the influence of socioeconomic deprivation. Br. J. Surg., 96, 74-80, 2009.
  4. Franco-Pons N., Gea-Sorlí S., Closa D. Release of inflammatory mediators by adipose tissue during acute pancreatitis. J. Pathol., 221, 175-182, 2010.
  5. Freeman M.: Reconsidering the effects of monosodium glutamate: a literature review. J. Am. Acad. Nurse Pract., 18, 10, 482-486, 2006.
  6. Frulloni L. et al.: Pancreatic hyperenzymemia: clinical significance and diagnostic approach. JOP. J. Pancreas (Online), 6, 536-51, 2006.
  7. Gullo L. Benign pancreatic hyperenzymemia or Gullo’s syndrome. JOP., 7, 241‑242, 2007.
  8. Khokhar A.S., Seidner D.L.: The pathophysiology of pancreatitis. Nutr. Clin. Pract., 19, 5-15, 2004.
  9. Nakagawa T. et al.:Effects of chronic administration of sibutramine on body weight, food intake and motor activity in neonatally monosodium glutamate-treated obese female rats: relationship of antiobesity effect with monoamines. Exp. Anim., 49, 239-249, 2000.
  10. Oida K. et al.: Plasma lipoproteins of monosodium glutamate-induced obese rats. Int. J. Obes., 8, 5, 385-391, 1984.
  11. Pandol S.J. et al.: Acute pancreatitis: bench to the bedside. Gastroenterology, 133, 1056, 1–25, 2007.
  12. Pereda J. et al.: Obese rats exhibit high levels of fat necrosis and isoprostanes in taurocholate-induced acute pancreatitis. PLoS ONE, 7, 9, 44383, 2012.
  13. Sandhu S. et al.: Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: A retrospective cohort study. Lipids Health Dis., 10, 157, 2011.
  14. Segersvärd R. et al.: Obesity alters cytokine gene expression and promotes liver injury in rats with acute pancreatitis. Obesity, 16, 23-28, 2008.
  15. Sempere L. et al.: Obesity and fat distribution imply a greater systemic inflammatory response and a worse prognosis in acute pancreatitis. Pancreatology, 8, 257-264, 2008.


June 2020

Mon Tue Wed Thu Fri Sat Sun
01 02 03 04 05 06 07
08 09 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30